Study of BI 764524 for diabetic retinopathy
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This study tests an investigational drug called BI 764524 for people with moderate to severe diabetic retinopathy, a complication of diabetes that can damage the retina. The goal is to see if the treatment can help prevent vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diabetes and are under a doctor's care for it
- You are 18 years or older
- You have moderate to severe non-proliferative diabetic retinopathy (a stage of diabetic eye disease)
- Your vision in the study eye is 20/100 or better
- You have not had certain eye surgeries or eye treatments recently
- No active abnormal blood vessel growth in the retina (except in specific cases)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage safety study testing a new medicine injected directly into the eye to treat diabetic retinopathy (damage to blood vessels in the retina caused by diabetes). The study checks if the medicine is safe and how the body processes it.
This study looks for specific eye findings (“biomarkers”) in people with type 2 diabetes using eye imaging. It may help researchers better understand diabetic retinopathy and how to detect it earlier or more accurately.
This trial tests if a new medicine (MK-8748) works as well as or better than the usual treatment (aflibercept) for people with diabetic macular edema, a condition that causes vision loss from diabetes-related swelling in the back of the eye.
This study tests a new approach aimed at improving diabetic eye disease (diabetic retinopathy). It may help by changing inflammation and related processes in the eye, especially in people who have diabetes and eye changes.
This trial tests a new medicine (MK-8748) against an existing treatment (aflibercept) for people with diabetic macular edema, which causes vision loss due to swelling in the back of the eye. The goal is to see which works better to improve or protect vision.
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
Hear when a new Diabetic Retinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.